Verona Pharma’s Ohtuvayre: Strong Performance and Growth Potential Drive Buy Rating
Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...
Verona Pharma price target raised to $60 from $42 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...
Investing13d
Roth/MKM initiates coverage on Verona Pharma stock with Buy rating and strong upside potential
Friday - Shares of Verona Pharma (NASDAQ:VRNA) received a positive outlook from Roth/MKM as the firm initiated coverage with a Buy rating and a 12-month price target of $68. The bullish stance is ...
Hosted on MSN14d
Roth MKM Initiates Coverage of Verona Pharma plc - Depositary Receipt () (VRNA) with Buy Recommendation
As of December 23, 2024, the average one-year price target for Verona Pharma plc - Depositary Receipt is $47.94/share. The forecasts range from a low of $36.36 to a high of $67.20.
Nasdaq15d
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in ...